Testing AK109 and AK104 for advanced stomach cancer treatment

Is this trial a fit for you?

A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.

What this trial studies

This clinical trial evaluates the effectiveness of AK109 and AK104, with or without chemotherapy, in patients with advanced gastric adenocarcinoma or gastroesophageal junction adenocarcinoma who have failed first-line treatments. It is a multicenter Phase Ib/II study designed to assess safety, tolerability, and preliminary efficacy of these interventions. Participants will receive either AK109, AK104, or paclitaxel as part of their treatment regimen. The study aims to provide new therapeutic options for patients with limited treatment alternatives.

Why it matters

Who can join: the full rules

Inclusion Criteria:

1. Written and signed informed consent
2. Age ≥ 18 years but ≤ 75 years
3. ECOG of 0 or 1.
4. Estimated life expectancy of ≥3 months.
5. Histologically or cytologically documented advanced unresectable or metastatic gastric adenocarcinoma or gastroesophageal Junction (GEJ) adenocarcinoma.
6. At least one measurable lesion per RECIST v1.1.
7. Gastric adenocarcinoma or gastroesophageal junction (GEJ) adenocarcinoma with failure of first-line treatment with anti-PD-1/L1 and chemotherapy
8. Adequate organ function.
9. Have agreed to take effective contraception from the date of signing the informed consent form until 120 days after the last administration.

Exclusion Criteria:

1. Other invasive malignancies within 3 years, except for locally treatable (manifested as cured) malignancies, such as basal or skin squamous cell carcinoma, superficial bladder cancer, cervical or breast carcinoma in situ.
2. Any previous systemic therapy targeting VEGF or anti-VEGFR signaling pathways.
3. In addition to PD1 or PD-L1,Prior exposure to anti-CTLA-4 antibody, or any other antibody or drug therapy for T cell co-stimulatory or checkpoint pathways, such as ICOS or agonists (e.g. CD40, CD137, GITR and OX40 etc).
4. Known history of primary immunodeficiency virus infection.
5. Known history of allogeneic organ transplantation or allogeneic hematopoietic stem cell transplantation.
6. Known history of interstitial lung disease.
7. Known history of active tuberculosis (TB).
8. Central nervous system (CNS) metastasis, meningeal metastasis, spinal cord compression, or leptomeningeal disease.
9. Patients with untreated chronic hepatitis B or HBV DNA exceeding 500IU/mL or active hepatitis C should be excluded. Patients with HCV antibody positive are eligible to participate in the study if the results of HCV RNA test show negative.
10. Known history of testing positive for human immunodeficiency virus (HIV).
11. Uncontrolled pleural effusion, pericardial effusion, or ascites requiring repeated drainage.
12. Subjects with active, known or suspected autoimmune disease, or a medical history of autoimmune disease, with the exceptions of the following: vitiligo, alopecia, Grave disease, psoriasis or eczema not requiring systemic treatment within the last 2 years, hypothyroidism (caused by autoimmune thyroiditis) only requiring steady doses of hormone replacement therapy and type I diabetes only requiring steady doses of insulin replacement therapy, or completely relieved childhood asthma that requires no intervention in adulthood, or primary diseases that will not relapse unless triggered by external factors.
13. Pregnant or lactating women.

Where it's running

• Beijing Cancer Hospital
  Beijing, China Recruiting

Study contacts

• Principal investigator: Lin Shen, MD — Peking University Cancer Hospital & Institute
• Study coordinator: Ting Liu, MD
• Email: clinicaltrials@akesobio.com
• Phone: +86 (0760) 8987 3999

Similar studies

Other studies for the same condition or treatment. Recruiting studies are listed first.

• SHR-1701 with chemotherapy for gastric/GEJ cancer with peritoneal spread

  This study tests whether SHR-1701 plus either paclitaxel-based therapy with intraperitoneal and intravenous delivery or CAPOX can help adults with gastric or GEJ adenocarcinoma that has spread to the peritoneum.

  Recruiting at 2 sites Phase 2 Ruijin Hospital · Shanghai, Shanghai Municipality and 1 other locations · NCT07384234

• Zolbetuximab with paclitaxel and ramucirumab for CLDN18.2-positive stomach and gastro‑esophageal junction cancer

  This treatment tests whether adding zolbetuximab to paclitaxel and ramucirumab helps adults with metastatic gastro‑esophageal adenocarcinoma whose tumors are CLDN18.2‑positive live longer.

  Recruiting Phase 2 Universitaire Ziekenhuizen KU Leuven · Antwerp and 5 other locations · NCT06962137

• AK157D1 injection for advanced solid tumors

  A first-in-human Phase 1 study tests AK157D1 injection in adults with unresectable advanced solid tumors to see if it is safe and tolerable and to get early signs of how it behaves in the body and against tumors.

  Recruiting Phase 1 Akeso · Harbin, Heilongjiang and 2 other locations · NCT07847281

• Cadonilimab with chemotherapy vs chemotherapy with/without nivolumab as first-line treatment for HER2-negative advanced gastric/GEJ cancer

  This study tests whether adding cadonilimab to chemotherapy helps people with newly diagnosed, unresectable or metastatic HER2-negative gastric/GEJ cancer live longer, compared with standard chemo alone (with or without nivolumab).

  Recruiting Phase 3 Akeso · Phoenix, Arizona and 24 other locations · NCT07700979

• A Phase II test of AK146D1 with AK112 in advanced NSCLC

  This phase II study tests whether AK146D1 together with AK112 or other cancer therapies can be safely given and help treat adults with advanced non-small cell lung cancer.

  Recruiting Phase 2 Akeso · Guangzhou, Guangdong · NCT07669779

• AK138D1 alone or with Ivonescimab in advanced non-small cell lung cancer

  This study tests AK138D1 by itself or with Ivonescimab in adults with advanced non-small cell lung cancer to see if it is safe and can help shrink tumors.

  Recruiting Phase 1/2 Akeso · Shanghai, Shanghai Municipality · NCT07623356

How to take part

1. Review the eligibility criteria above with your treating physician.
2. Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
3. Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.